| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
GH18 Chitinases[1]
Bisdionin C targets GH18 chitinases, including acidic mammalian chitinase (AMCase), chitotriosidase (CHIT1), and bacterial AfChiB1 chitinase. These enzymes are involved in the hydrolysis of chitin, a polysaccharide found in arthropod exoskeletons and fungal cell walls. By inhibiting chitinases, bisdionin C modulates chitin metabolism and immune responses. |
|---|---|
| ln Vitro |
Bisdionin C demonstrates potent in vitro inhibition of GH18 chitinases. It has an IC50 of 0.2 μM against AfChiB1, 3.4 μM against AMCase, and 8.3 μM against HCHT. The compound's potent activity makes it a valuable tool for studying chitinase biology and potential therapeutic applications in conditions involving chitinase dysregulation.
|
| ln Vivo |
In vivo activity of bisdionin C has not been extensively documented. Its potent inhibition of chitinases suggests potential for in vivo efficacy in models of chitinase-related diseases, such as asthma, fungal infections, and inflammatory conditions. Further in vivo studies are needed to evaluate its pharmacokinetic properties, efficacy, and safety.
|
| Enzyme Assay |
In vitro enzyme assays for bisdionin C involve measuring its inhibition of chitinase activity using fluorogenic substrates such as 4-methylumbelliferyl β-D-N,N',N''-triacetylchitotrioside (4-MU-β-D-GlcNAc3). The assay typically uses purified recombinant chitinase enzymes, and IC50 values are determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for bisdionin C involve treating cells or tissues with varying concentrations of the compound and measuring chitinase activity or chitin degradation. The compound's effects on immune responses can be assessed by measuring cytokine production in chitin-stimulated immune cells.
|
| Animal Protocol |
In vivo animal experiments for bisdionin C are not extensively documented. If used in animal models, typical protocols would involve administering the compound to models of asthma, fungal infection, or inflammation and evaluating efficacy by measuring chitinase activity, inflammatory markers, or disease progression.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for bisdionin C are limited. The compound has a molecular weight of 400.39 and a molecular formula of C17H20N8O4. Its absorption, distribution, metabolism, and excretion properties have not been characterized. Purity is ≥98% by HPLC.
|
| Toxicity/Toxicokinetics |
Toxicological data for bisdionin C are limited. As a research compound, comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Schüttelkopf AW, et al. Bisdionin C-a rationally designed, submicromolar inhibitor of family 18 chitinases. ACS Med Chem Lett. 2011;2(6):428-432. Published 2011 Mar 23.
|
| Additional Infomation |
Bisdionin C (CAS#: 74857-22-0) has the molecular formula C17H20N8O4 and a molecular weight of 400.39. It is a potent GH18 chitinase inhibitor with IC50s of 0.2 μM (AfChiB1), 3.4 μM (AMCase), and 8.3 μM (HCHT). The compound is used in research on chitinase biology. Purity is ≥98%.
|
| Molecular Formula |
C17H20N8O4
|
|---|---|
| Molecular Weight |
400.39
|
| Exact Mass |
400.161
|
| CAS # |
74857-22-0
|
| PubChem CID |
5025063
|
| Appearance |
White to off-white solid powder
|
| LogP |
-0.4
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
687
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2=C(N=CN2C)N(C)C(N1CCCN1C(N(C)C2=C(C1=O)N(C)C=N2)=O)=O
|
| InChi Key |
KEPIKAFUZRKZMT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H20N8O4/c1-20-8-18-12-10(20)14(26)24(16(28)22(12)3)6-5-7-25-15(27)11-13(19-9-21(11)2)23(4)17(25)29/h8-9H,5-7H2,1-4H3
|
| Chemical Name |
1-[3-(3,7-dimethyl-2,6-dioxopurin-1-yl)propyl]-3,7-dimethylpurine-2,6-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 2 mg/mL (5.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4976 mL | 12.4878 mL | 24.9756 mL | |
| 5 mM | 0.4995 mL | 2.4976 mL | 4.9951 mL | |
| 10 mM | 0.2498 mL | 1.2488 mL | 2.4976 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
